X4 Pharmaceuticals (XFOR) Research & Development (2017 - 2025)

X4 Pharmaceuticals (XFOR) has 9 years of Research & Development data on file, last reported at $18.5 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 14.66% year-over-year to $18.5 million; the trailing twelve-month figure through Dec 2025 stood at $72.7 million (down 10.93% YoY), and the FY2025 full-year result was $72.7 million, down 10.93% from the prior year.
• Research & Development for Q4 2025 stood at $18.5 million, up from $17.3 million in the prior quarter.
• Across five years, Research & Development topped out at $22.1 million in Q1 2023 and bottomed at $12.1 million in Q1 2021.
• The 5-year median for Research & Development is $17.8 million (2025), against an average of $16.9 million.
• The widest annual swing landed in 2022, when Research & Development soared 56.34%; it then declined 19.68% in 2023.
• A 5-year view of Research & Development shows it stood at $12.2 million in 2021, then soared by 56.34% to $19.0 million in 2022, then slipped by 19.68% to $15.3 million in 2023, then surged by 42.1% to $21.7 million in 2024, then retreated by 14.66% to $18.5 million in 2025.
• The last three Research & Development figures came in at $18.5 million (Q4 2025), $17.3 million (Q3 2025), and $18.4 million (Q2 2025), per Business Quant data.

Peer Comparison